Please check this page for announcements from CDDG, including new partnerships, upcoming meetings and other important company news to pass along.
CDDG Announces a new partnership with pharmefex
Seattle, WA, March 5, 2018 - Cascadia Drug Development Group (CDDG; theCDDG.com) and Pharmefex (pharmefex.com) are pleased to announce the formation of a strategic partnership. CDDG provides oversight of drug development from discovery to early clinical development and offers subject matter expertise in several key translational sciences through their network of vetted affiliates. Pharmefex helps organizations to streamline process development, accelerate time to market, reduce cost of goods, manage technology transfers, prepare CMC submissions, and prevent and resolve manufacturing and compliance problems for recombinant proteins, and cellular immunotherapy products. This partnership is based on shared standards of quality and expands the scope of outstanding service CDDG and Pharmefex can provide their clients.
Cascadia Drug Development Group Announces New Clients
Seattle, WA, August 21, 2017 - Cascadia Drug Development Group’s mission is to provide a sustainable platform for therapeutic development and biotech creation in the Pacific Northwest and beyond. We’re pleased to announce two new client partnerships that represent an important step in that direction.
CDDG has entered into a working relationship with Amdax Therapeutics, a new biotech company spun out of the University of Washington’s Division of Rheumatology. CDDG is providing strategic guidance to the Amdax scientific leadership team in order to help execute a preclinical program with potential for the treatment of autoimmune disease.
CDDG has also been retained by Celimmune to help them advance a promising new treatment for celiac disease, a gluten-triggered immune response that impacts approximately 1% of the general population and can cause debilitating symptoms and potentially serious medical complications. Though rare, in non-responsive celiac disease (NRCD) and refractory celiac disease (RCD), abstinence from gluten alone does not resolve the symptoms and RCD type II can presage development of malignant EATL, a peripheral T cell lymphoma with poor prognosis/survival. Celimmune has completed two Phase 2 clinical trials (in NRCD and RCD-II, link) with assistance from CDDG and will be presenting results at upcoming scientific conferences. To learn more about how CDDG and our flexible operating model can help your biotech or startup succeed, just contact us.